Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
CSPC PHARMA (01093.HK) Receives USD1.2B Upfront Payment from AstraZeneca, Positive Contribution to Financial Position
Recommend 5 Positive 13 Negative 0 |
||||
|
||||
|
CSPC PHARMA (01093.HK) announced that it received an upfront payment of USD1.2 billion from AstraZeneca on May 29, 2026 (after trading hours). The receipt of the upfront payment will have a positive contribution to the Groups financial position. The Group previously entered into a strategic research and development collaboration and licensing agreement with AstraZeneca to leverage the Groups proprietary long-acting delivery technology platform and peptide drug AI discovery platform to develop innovative long-acting peptide drugs. Pursuant to the terms of the agreement, the Group will receive, among other things, an upfront payment of USD1.2 billion. (ad/da) Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
